UCB (OTCMKTS:UCBJF) Stock Price Up 7.4% – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) shares shot up 7.4% during trading on Wednesday . The stock traded as high as $304.96 and last traded at $304.96. 38 shares were traded during mid-day trading, a decline of 96% from the average session volume of 919 shares. The stock had previously closed at $284.00.

Analysts Set New Price Targets

UCBJF has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of UCB in a research note on Monday, December 8th. Wolfe Research initiated coverage on UCB in a report on Monday, February 23rd. They set an “outperform” rating on the stock. Barclays restated an “overweight” rating on shares of UCB in a research report on Tuesday, January 6th. Stephens reiterated an “overweight” rating on shares of UCB in a research report on Thursday, January 15th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a research note on Monday, February 16th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy”.

UCB Trading Up 7.4%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average price of $312.11 and a two-hundred day moving average price of $287.19.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.